Is RNA or RNXT more undervalued in 2026?

CirclFi compares Atrium Therapeutics, Inc. (RNA) and RenovoRx, Inc. (RNXT) using 13 institutional-grade valuation models. RNA has a Quality of Company score of 1.7/10 while RNXT scores 5.0/10.

Which is a better buy — RNA or RNXT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RNA and RNXT valuations compare?

RNA at $13.36 and RNXT at $0.99 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RNA vs RNXT Valuation Comparison 2026 — Intrinsic Value Analysis

RNA

Biotechnology

Atrium Therapeutics, Inc.

Quality

1.7

out of 10

Value Trap

—

Price

$13.36

Last close

Models

9/13

Active

RNXT

Biotechnology

RenovoRx, Inc.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$0.99

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	RNA Fair Value	RNA Upside	RNXT Fair Value	RNXT Upside
Bayesian DCF	Intrinsic	$3.54	-73.5%	$0.41	-58.2%
Earnings Power Value	Intrinsic	$5.25	-61.1%	$1.13	+27.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RNA vs RNXT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RNA vs RNXT — Which Stock Is More Undervalued?

RNXT scores higher with a 5.0/10 quality rating vs RNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Atrium Therapeutics, Inc. (RNA) and RenovoRx, Inc. (RNXT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RNA currently trades at $13.36 with a QOC of 1.7/10, while RNXT trades at $0.99 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).